The company has not filed an annual or quarterly report since its Q2 FY2020 10-Q, filed Aug 6, 2020. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q2 FY2020, filed Aug 6, 2020
The sections below describe the company as of the FY2019 annual report.
Develops oral and topical small-molecule drug candidates for people with immune-mediated diseases, including conditions affecting the skin, blood and central nervous system.
10-K for FY2019, filed Mar 10, 2020We are a late-stage biopharmaceutical company focused on developing novel therapies for immune-mediated diseases. Our proprietary Tailored…View ↗
We have developed a BTK inhibitor franchise that encompasses two differentiated oral drug candidates, rilzabrutinib and PRN2246/SAR442168…View ↗
ITPView ↗
BTK Inhibitor for CNS Diseases: PRN2246/SAR442168View ↗
Receives upfront license fees when rights are transferred, milestone payments when development, regulatory or commercial milestones are achieved, and royalties tied to partner product sales.
10-K for FY2019, filed Mar 10, 2020PRN2246/SAR442168 is designed to treat MS and potentially other CNS diseases, in part by inhibiting B cells and other immune cells in the…View ↗
Licenses of Intellectual Property: If the license to our intellectual property is determined to be distinct from the other performance…View ↗
Milestone Payments: At the inception of each arrangement that includes development, regulatory or commercial milestone payments, we…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license…View ↗
$35.2M
10-K for FY2019, filed Mar 10, 2020
$35.2M ↗
Sanofi holds an exclusive license to develop PRN2246/SAR442168 and is responsible for its further clinical development. Principia also had a collaboration with AbbVie, which ended.
10-K for FY2019, filed Mar 10, 2020PRN2246/SAR442168 is designed to treat MS and potentially other CNS diseases, in part by inhibiting B cells and other immune cells in the…View ↗
We have discovered multiple series of highly selective, oral small molecule inhibitors of the immunoproteasome. In June 2017, we formed a…View ↗
Collaborate with our partner Sanofi to advance PRN2246/SAR442168, our BTK inhibitor that we designed to cross the blood-brain barrier…View ↗
8-K, filed Sep 28, 2020
Following the completion of the Offer, on September 28, 2020, pursuant to the terms of the Merger Agreement and in accordance with Section…View ↗
8-K, filed Aug 17, 2020
Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Purchaser will commence a cash tender offer (the…View ↗
Competes with AbbVie, AstraZeneca, Biogen, Bristol-Myers Squibb, Genentech, Gilead, Innocare, Merck KGaA, Novartis, and Taiho
10-K for FY2019, filed Mar 10, 2020There are a number of BTK inhibitors in development. These competitive BTK inhibitors span across multiple indications that may or may not…View ↗
Loading...
